Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration

References

• Andrianov AK, Payne LG. Polymeric carriers for oral uptake of microparticlulates. Adv Drug Deliv Rev 1998; 34: 155–170
   PubMed Web of Science ®Google Scholar
• Bargoni A, Cavalli R, Caputo O, Fundaro A, Gasco MR, Zara GP. Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats. Pharm Res 1998; 15(5)745–750
   PubMed Web of Science ®Google Scholar
• Caliph SM, Charman WN, Porter CJH. Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of haofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. J Pharm Sci 2000; 89(8)1073–1084
   PubMed Web of Science ®Google Scholar
• Cavalli R, Bargoni A, Podio V, Muntoni E, Zara GP, Gasco MR. Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J Pharm Sci 2003; 92(5)1085–1094
   PubMed Web of Science ®Google Scholar
• Charman WN. Lipids, lipophilic drugs, and oral drug delivery—some emerging concepts. J Pharm Sci 2000; 89(8)967–978
   PubMed Web of Science ®Google Scholar
• Chen Da-B, Yang T-Z, Lu W-L, Zhang Q. In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem Pharm Bull 2001; 49(11)1444–1447
   PubMed Web of Science ®Google Scholar
• Couvreur P, Dubernet C, Puisieux F. Control drug delivery with nanoparticles: Current possibilities and future trend. Eur J Pharm Biopharm 1995; 41: 2–13
   Web of Science ®Google Scholar
• Demirel M, Yazan Y, Muller RH, Kilic F, Bozan B. Formulation and in vitro–in vivo evaluation of piribedil solid lipid micro- and nanoparticles. J Microencapsul 2001; 18(3)359–371
   PubMed Web of Science ®Google Scholar
• El-Shabouri MH. Positively charged nanoparticles for improving the oral bioavailability of cyclosporine-A. Int J Pharm 2002; 249: 101–108
   PubMed Web of Science ®Google Scholar
• Eldridge JH, Hammond CJ, Meulbrock JA, Staas JK, Gilley RM, Tice TR. Controlled vaccine release in the gut associated lymphoid tissue. I. Orally administered biodegradable microspheres target the Peyer's patches. J Control Release 1990; 11: 205–214
   Web of Science ®Google Scholar
• Florence AT, Hillery AM, Hussain N, Jani PU. Nanoparticles as carriers for oral peptide absorption: studies on particles uptake and fate. J Control Release 1995a; 36: 39–46
   Web of Science ®Google Scholar
• Florence AT, Hillery M, Jani PU. Factors affecting the oral uptake and translocation of polystyrene nanoparticles: Histological and analytical evidence. J Drug Target 1995b; 3: 65–70
   PubMed Web of Science ®Google Scholar
• Florence D. Evaluation of nano- and microparticles uptake by the gastrointestinal tract. Adv Drug Deliv Rev 1998; 34: 221–233
   PubMed Web of Science ®Google Scholar
• Fundaro A, Cavalli R, Bargoni A, Vighitto D, Zara GP, Gasco MR. Non stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: Pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmocol Res 2000; 42(4)337–343
   PubMed Web of Science ®Google Scholar
• Gabizon A, Demetrios P. The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim Biophy Acta 1992; 1103: 94–100
   PubMed Web of Science ®Google Scholar
• Gasco MR. 1993. Methods for producing solid lipid microparticles having a narrow size distribution, United States Patents, USS 188837
   Google Scholar
• Gopper TM, Muller RH. Plasma protein adsorption of tween 80 and poloxamer 188-stabilized solid lipid nanoparticles. J Drug Target 2003; 11: 225–231
   PubMed Web of Science ®Google Scholar
• Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80 coated nanoparticles. Pharm Res 1999; 16(10)1564–1569
   PubMed Web of Science ®Google Scholar
• Hauss DJ, Fogal SE, Ficorilli JV, Price CA, Roy T, Jayaraj AA, Keirns JJ. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water soluble LTB4 inhibitor. J Pharm Sci 1998; 87: 164–169
   PubMed Web of Science ®Google Scholar
• Ishida T, Harashima H, Kiwada H. Interactions of liposomes with cells in vitro and in vivo: Opsonins and receptors. Curr Drug Metab 2001; 2: 397–409
   PubMed Web of Science ®Google Scholar
• Jani PU, Halbert GW, Langridge J, Florence AT. Uptake and translocation of latex nanospheres and microspheres after oral administration to rats. J Pharm Pharmacol 1989; 41: 809–812
   PubMed Web of Science ®Google Scholar
• Jankowski A, Lamparczyk H. Evaluation of chromatographic methods for the determination of nifedipine in human serum. J Chromatogr A 1994; 668: 469–473
   PubMed Web of Science ®Google Scholar
• Jepson MA, Simmons NL, O'Hagan DT, Hirst BH. Compression of poly (dl-lactide-co-glycolid) and polystyrene microspheres targeting to intestinal M cells. J Drug Target 1993; 1: 245–249
   PubMed Web of Science ®Google Scholar
• Kann J, Krol GJ, Raemsch KD. Bioequivalence and metabolism of nitrendipine administered orally to healthy volunteers. J Cadriovasc Pharmacol 1984; 6: S968–S973
   PubMed Web of Science ®Google Scholar
• Khoo SM, Humberstone AJ, Porter CJH, Edwards GA, Charman WN. Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine. Int J Pharm 1998; 167: 155–164
   Web of Science ®Google Scholar
• Kraus HP, Ahr HJ, Beerman D, Siefert HM, Suwelack D, Weber H. I. The pharmacokinetics of nitrendipine, absorption, plasma concentrations, and excretion after single administration of [14C] nitrendipine to rats and dogs. Arzneim Forsch Drug Res 1988; 38: 1593–1599
   PubMed Web of Science ®Google Scholar
• Kreuter J. Peroral administration of nanoparticles. Adv Drug Deliv Rev 1991; 7: 71–86
   Web of Science ®Google Scholar
• Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001; 47: 65–81
   PubMed Web of Science ®Google Scholar
• Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. Passage of peptides through the blood brain-barrier with colloidal polymeric particles (nanoparticles). Brain Res 1995; 674: 171–174
   PubMed Web of Science ®Google Scholar
• MacGregor KJ, Embleton JK, Lacey JE, Perry EA, Solomon LJ, Seager H, Pouton CW. Influence of lipolysis on drug absorption from the gastrointestinal tract. Adv Drug Del Rev 1997; 25: 33–46
   Web of Science ®Google Scholar
• Mikus G, Eichelbaum M. Pharmacokinetics, bioavailability, metabolism and hemodynamic effect of the calcium channel antagonist, nitrendipine. J Cardiol Pharmacol 1987; 9: S140–S141
   Google Scholar
• Muller RH, Mehenert W, Lucks JS, Schwarz C, zur Muhlen A, Weyhers H, Freitas C, Ruhl D. Solid lipid nanoparticles (SLN)—an alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm 1995; 41: 62–69
   Web of Science ®Google Scholar
• Muller RH, Ruhl D, Runge SA. Biodegradation of solid lipid nanoparticles as function of lipase incubation time. Int J Pharm 1996; 144: 115–121
   Web of Science ®Google Scholar
• Nishioka Y, Yoshino H. Lymphatic targeting with nanoparticulate system. Adv Drug Deliv Rev 2001; 47: 55–64
   PubMed Web of Science ®Google Scholar
• Norris DA, Puri N, Sinko PJ. The effect of physical barrier and properties on the oral absorption of particulates. Adv Drug Deliv Rev 1998; 34: 135–154
   PubMed Web of Science ®Google Scholar
• O'Driscoll CM. Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci 2002; 15: 405–415
   PubMed Web of Science ®Google Scholar
• Olbrich C, Muller RH. Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures. Int J Pharm 1999; 180: 31–39
   PubMed Web of Science ®Google Scholar
• Olbrich C, Kayser O, Muller RH. Lipase degradation of Dynasan 114 and 116 solid lipid nanoparticles (SLN)-effect of surfactants, storage time and crystallinity. Int J Pharm 2002; 237: 119–128
   PubMed Web of Science ®Google Scholar
• Park YS, Maruyama K, Huang L. Some negatively charged phospholipids derivatives prolong the liposome circulation in vivo. Biochim Biophys Acta 1992; 1108: 257–260
   PubMed Web of Science ®Google Scholar
• Penkler L, Muller RH, Runge SA, Ravelli V. 1999. PCT-application, PCT/EP99/02892 Pharmaceutical cyclosporine formulation with improved biopharmaceutical properties, improved physical quality, greater stability and method for producing said formulation.
   Google Scholar
• Podio V, Zara ZP, Carazzone M, Cavalli R, Gasco MR. Biodistribution of stealth and non-stealth solid lipid nanospheres after intravenous administration to rats. J Pharm Pharmcol 2000; 52: 1057–1063
   PubMed Web of Science ®Google Scholar
• Porter CJH, Charman WN. Lipid based formulations for oral administration: Opportunities for bioavailability enhancement and lipoprotein targeting of lipophilic drugs. J Recept Signal Transduct Res 2001; 21(2–3)215–257
   PubMed Web of Science ®Google Scholar
• Porter CJH, Charman SA, Charman WN. Lymphatic transport of halofantrine in the conscious rat administered as either the free base or the hydrochloride salt: Effect of lipid class and lipid vehicle dispersion. J Pharm Sci 1996; 85: 357–361
   PubMed Web of Science ®Google Scholar
• Rojanasakul Y, Wang LY, Bhat M, Glover DD, Malanga CJ, Ma JKH. The transport barrier of epithelia: A comparative study on membrane permeability and charge selective in the rabbits. Pharm Res 1992; 9: 1029–1034
   PubMed Web of Science ®Google Scholar
• Rose MR, David R. Drugs used for the treatment of myocardial ischemia. Goodman and Gilman's the pharmacological basis of therapeutics9th ed., PerryB Molinoff, RW Ruddon. Mc Graw-Hill. 1996; 759–779
   Google Scholar
• Schroeder U, Sommerfeld P, Ulrich S, Sabel BA. Nanoparticle technology for delivery of drugs across the blood brain barrier. J Pharm Sci 1998; 87(11)1305–1307
   PubMed Web of Science ®Google Scholar
• Simon BH, Ando HY, Gupta PK. Circulation time and body distribution of 14C-labelled amino-modified polystyrene nanoparticles in mice. J Pharm Sci 1995; 84(10)1249–1253
   PubMed Web of Science ®Google Scholar
• Soons PA, Breimer DD. Stereoselective pharmacokinetics of oral and intravenous nitrendipine in healthy male subjects. Br J Clin Pharmacol 1991; 32: 11–16
   PubMed Web of Science ®Google Scholar
• Sun W, Xie C, Wang H, Hu Y. Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain. Biomaterials 2004; 25: 3065–3071
   PubMed Web of Science ®Google Scholar
• Suresh RJ, Venkateswarlu V. Novel delivery systems for drug targeting to brain. Drugs Future 2004; 29(1)63–83
   Web of Science ®Google Scholar
• Swartz MA. The physiology of the lymphatic system. Adv Drug Deliv Rev 2001; 50: 3–20
   PubMed Web of Science ®Google Scholar
• Thomson ABR, Schoeller C, Keelan M, Smith L. Lipid absorption: Passing through the unstirred layers, brush border membrane and beyond. Can J Physiol Pharmacol 1993; 71: 531–555
   PubMed Web of Science ®Google Scholar
• Ueda CT, Lemaire M, Gsell G, Nussbaumer K. Intestinal lymphatic absorption of cyclosporin A following oral administration in an olive oil solution to rats. Biopharm Drug Dispos 1983; 4: 113–124
   PubMed Web of Science ®Google Scholar
• Venkateswarlu V, Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release 2004; 95: 627–638
   PubMed Web of Science ®Google Scholar
• Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release 1999a; 59: 299–307
   PubMed Web of Science ®Google Scholar
• Yang S, Zhu J, Lu Y, Liang B, Yang C. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res 1999b; 16(5)751–757
   PubMed Web of Science ®Google Scholar
• Zara GP, Bargoni A, Cavalli R, Fundaro A, Vighetto D, Gasco MR. Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. J Pharm Sci 2002a; 91(5)1324–1333
   PubMed Web of Science ®Google Scholar
• Zara GP, Cavalli R, Bargoni A, Fundaro A, Vighitto D, Gasco MR. Intravenous administration to rabbits of non stealth and stealth doxorubicin loaded solid lipid nanoparticles at increasing concentrations of stealth agent: Pharmacokinetics and distribution of doxorubicin in brain and other tissues. J Drug Target 2002b; 10(4)327–335
   PubMed Web of Science ®Google Scholar